Humira has a longstanding track record and the widest array of approved indications of any of the TNF-a drugs, so the results reported in #msg-76323506 will cause round-off error, at most, in Humira’s sales ramp.
What could affect Humira sales in a non-trivial way are: i) an oral drug such as PFE’s Tofacitinib; and ii) an interchangeable FoB from BAX/MNTA (which is several years away from possibly reaching the market).
Market Data 
Markets 
AI
